Tuesday, September 10, 2013
• Astellas Pharma Inc., of Tokyo, said in liver transplant patients, initiating Advagraf prolonged-release capsules (tacrolimus) therapy immediately post-transplant, at a dose 25 percent lower than the upper recommended limit, in combination with basiliximab, resulted in significantly better renal function and a lower incidence of acute organ rejection when compared with standard dose Advagraf therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.